Australia markets closed

Biomea Fusion, Inc. (BMEA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.80-0.94 (-8.75%)
At close: 04:00PM EST
9.80 0.00 (0.00%)
After hours: 06:03PM EST
Full screen
Trade prices are not sourced from all markets
Previous close10.74
Bid8.62 x 800
Ask9.79 x 800
Day's range9.65 - 10.91
52-week range9.65 - 22.22
Avg. volume123,154
Market cap284.639M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est26.00
  • GlobeNewswire

    Biomea Fusion to Participate in Two Upcoming Investor Conferences

    REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with genetically defined cancers, today announced that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in two upcoming virtual conferences. Jefferies London Healthcare Conference Fireside chat on

  • GlobeNewswire

    Biomea Fusion Publishes Abstract on BMF-219 at ASH Annual Meeting

    Figure 1 Menin and various co-factors Figure 2 Transcription factor (TF) activity inference using ChIP-seq of differentially expressed genes in MOLM-13 cells incubated with 500 nM BMF-219 at 24 hours. Each bar represents a study in the GEO repository using the specified TF antibody. TFs with more than one bar represent multiple study sets in GEO that overlap with BMF-219 mediated differentially expressed genes. MYC and MAX are top TFs regulating this subset of differentially expressed genes (p=1

  • GlobeNewswire

    Biomea Fusion Reports Third Quarter 2021 Financial Results and Business Highlights

    Announced FDA clearance of Investigational New Drug Application (IND) for BMF-219, the company’s first development candidate from the FUSION platformPhase I trial to enroll adult patients with relapsed or refractory acute leukemia, including those with an MLL/KMT2A gene rearrangement or NPM1 mutationScientific rationale for irreversible menin inhibition in diffuse large B cell lymphoma (DLBCL) now expected in Q4 2021Pathway validation in diabetes anticipated in Q1 2022Opened Biomea Innovation Re